The global closed system transfer devices market was valued at USD 465.8 million in 2020 and is projected to grow at a CAGR of 19.8% during the forecast period. Factors driving the growth of the closed system transfer devices market include rising cancer cases globally, improving regulatory guidelines concerning safe usage of risky drugs and increasing oncology medicine approvals.
A closed-system drug-transfer device is an assembly that automatically disallows the transfer of environmental pollutants into the system and the outflow of hazardous drug or vapour outside the system. These devices comprise a process to access the intravenous infusion and a leak-proof assembly that tries to transfer drugs devoid of leaks or spillage, as a minimum.
Regionally, North America accounted for the largest market share of the global closed system transfer devices market attributable to upsurge seen in cancer cases. Leading players of the global closed system transfer devices market include Becton, Dickinson and Company, Equashield LLC., ICU Medical, Inc., B. Braun Melsungen AG, Yukon Medical, Corvida Medical, CODAN Medizinische Geräte GmbH & Co KG, JMS Co., Ltd., Baxter International, Inc., VICTUS, among others.
Closed System Transfer Devices Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 1,963.2 million|
|Growth Rate||CAGR of 19.8% during 2021-2028|
|Segment Covered||Type, Component, End-use, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East & Africa|
|Key Players Profiled||Becton, Dickinson and Company, Equashield LLC., ICU Medical, Inc., B. Braun Melsungen AG, Yukon Medical, Corvida Medical, CODAN Medizinische Geräte GmbH & Co KG, JMS Co., Ltd., Baxter International, Inc., VICTUS, among others.|
Key segments of the global closed system transfer devices market
Type Overview, 2018-2028 (USD Million)
- Membrane-to-membrane systems
- Needleless systems
Component Overview, 2018-2028 (USD Million)
- Vial access devices
- Syringe safety device
- Bag/line access devices
End-use Overview, 2018-2028 (USD Million)
- Oncology centers & clinics
- Other end users
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Asia Pacific
- South America
- Middle East & Africa
Reasons for the study
- Rising prevalence of cancer
- Increasing number of oncology drug approvals
- Increasing use of closed system transfer devices to combat the harmful effects of cytotoxic or antineoplastic drugs
What does the report include?
- The study on the global closed system transfer devices market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type, component and end-use. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global closed system transfer devices market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global closed system transfer devices market
Consultants, analysts, researchers, and academicians looking for insights shaping the global closed system transfer devices market
Cancer is the foremost cause of death worldwide, experts anticipate its numbers to double before 2030. The precarious handling of hazardous drugs used to treat various types of cancer was acknowledged long back as a major health peril to workers. Studies have revealed that personnel can be at a threat of exposure to these drugs during their lifecycle from creation to delivery to use in the clinical or home care setting and all the way through to waste discarding. Healthcare workforces who handle these drugs may be exposed by inhaling dust or aerosols produced through pharmacy preparation and nursing administration, or by straight contact with the skin in the course of fortuitous spill cleanup, needlesticks, or spills. The deadliness of hazardous drugs and the vulnerabilities of continued exposure to them have been recognized to cause infertility, hair loss, miscarriage, skin rashes, birth defects, and even leukemia and other forms of cancers among healthcare staffs.
The global closed system transfer devices market is categorized based on type, component and end-use.
By type: The membrane-to-membrane systems dominated the market in 2020 due to simplicity of procedure and the lesser hazard of contamination linked with double-membrane containment systems.
By end-use: In 2020, hospitals accounted for the largest share of the global closed system transfer devices market owing to the capability to buy expensive CSTDs, enormous number of cancer patients, and the growing requisite to conform with the regulatory guidelines recognized by the FDA and NIOSH about the protection of healthcare workers.
North America dominated the market for closed system transfer devices in 2020. The use of a closed system transfer device (CSTD) in combination with other safety provisions for instance gloves, masks, gowns, and vented preparation hoods offers a demonstrated way to surge safety levels when preparing, moving, governing, and disposing of dangerous drugs. NIOSH and The United States Pharmacopeia’s (USP) General Chapter 797 mention using a CSTD to lessen occupational contacts to hazardous medications. Numerous studies have proven the efficiency of CSTDs in decreasing airborne discharge, surface contamination, and exposure to healthcare personnel. One study equated surface contamination through 22 US hospital pharmacies after preparation with typical drug preparation procedures against a CSTD. The study showed a substantial decrease in intensities of contamination for all drugs sampled ifosfamide, cyclophosphamide, and 5-fluorouracil by 90%, 95%, and 65% correspondingly.